Eli Lilly and Company $LLY Shares Bought by Mitsubishi UFJ Asset Management Co. Ltd.

Key Points

• Mitsubishi UFJ Asset Management increased its Eli Lilly stake by 7% in the second quarter, bringing its holdings to 2.01 million shares valued at approximately $2.42 billion. Institutional investors collectively own 82.53% of LLY.
• Eli Lilly reported strong quarterly results, with revenue up 47.7% year over year and earnings of $8.38 per share versus the $6.40 analyst consensus. Analysts maintain a “Moderate Buy” consensus and an average price target of $1,292.18.
• LLY shares opened at $1,257.26, near their 52-week high, while insiders sold 13,500 shares worth about $16 million over the past three months. Growth prospects remain tied to obesity treatments and pipeline expansion, but competition from Novo Nordisk in oral GLP-1 drugs remains a risk.

Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 7.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,013,696 shares of the company's stock after buying an additional 131,669 shares during the quarter. Eli Lilly and Company makes up 1.3% of Mitsubishi UFJ Asset Management Co. Ltd.'s investment portfolio, making the stock its 13th largest position. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.21% of Eli Lilly and Company worth $2,415,287,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of LLY. Vanguard Group Inc. boosted its position in Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company's stock worth $88,087,193,000 after acquiring an additional 1,006,885 shares during the last quarter. State Street Corp raised its holdings in Eli Lilly and Company by 1.8% in the 4th quarter. State Street Corp now owns 35,361,916 shares of the company's stock valued at $38,002,744,000 after acquiring an additional 635,358 shares during the last quarter. Morgan Stanley raised its holdings in Eli Lilly and Company by 2.7% in the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company's stock valued at $16,757,510,000 after acquiring an additional 407,166 shares during the last quarter. Capital World Investors lifted its stake in shares of Eli Lilly and Company by 0.4% during the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company's stock worth $16,154,619,000 after purchasing an additional 61,851 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Eli Lilly and Company by 10.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company's stock worth $16,024,022,000 after purchasing an additional 1,432,069 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the firm's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 in the last three months. 0.14% of the stock is currently owned by company insiders.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly will collaborate with Boston-based Chai Discovery on an RNA vaccine platform. The partnership could expand Lilly’s technology and early-stage pipeline, though the financial impact is likely to be longer term. Lilly to work with Boston-based firm to develop RNA vaccine platform
• Positive Sentiment: Recent coverage continues to highlight Lilly’s momentum in obesity treatment, with its products reportedly outpacing Novo Nordisk’s offerings. This reinforces expectations for sustained demand and supports LLY’s growth narrative. Eli Lilly's obesity treatments outpace Novo Nordisk
• Positive Sentiment: Analyst-focused coverage identifies Eli Lilly as a leading candidate for significant earnings growth and a potential buy point as the broader market rebounds. These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Eli Lilly Tops Buy Point
• Neutral Sentiment: Lilly completed or advanced several clinical studies, including trials involving hidradenitis suppurativa, lebrikizumab, LY4178256 and eloralintide. The updates broaden the pipeline, but no decisive efficacy or regulatory results were provided. Lilly clinical-trial updates
• Neutral Sentiment: Discussion of a possible stock split reflects the sharp rise in LLY’s share price, but a split would not change the company’s fundamental value or earnings outlook. Stock Split Watch: Is Eli Lilly Stock Next?
• Negative Sentiment: Lilly continues to face competition from Novo Nordisk in the emerging oral GLP-1 market. The race creates substantial growth potential but also raises execution and market-share risks. Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race?

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on LLY shares. Citigroup lifted their price objective on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a "buy" rating in a research report on Wednesday, July 15th. JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 7th. Wall Street Zen lowered Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Sunday. UBS Group set a $1,376.00 price target on Eli Lilly and Company in a report on Friday, August 7th. Finally, Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a "hold" rating in a research note on Monday, June 22nd. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $1,292.18.

Eli Lilly and Company Stock Up 1.0%

Shares of NYSE LLY opened at $1,257.26 on Friday. Eli Lilly and Company has a 52-week low of $694.23 and a 52-week high of $1,292.65. The firm has a fifty day moving average of $1,180.14 and a 200-day moving average of $1,059.82. The stock has a market capitalization of $1.18 trillion, a PE ratio of 42.19, a P/E/G ratio of 1.48 and a beta of 0.51. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business's revenue for the quarter was up 47.7% on a year-over-year basis. During the same period in the prior year, the firm posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts anticipate that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company's dividend payout ratio is currently 23.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source